SCHEMBL5545243

SCHEMBL5545243

Cn1c(=O)c(C(=O)NCCCN2CCCC2)c(O)c2ncc(Cc3ccc(F)cc3)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
KCNH2 Q12809 1/20 0.44
HTR4 Q13639 1/20 0.44
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
CACNA1G O43497 3/20 0.42
HSD17B10 Q99714 2/20 0.42
RAD52 P43351 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 2/20 0.41
TSHR P16473 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
TP53 P04637 2/20 0.41
ALOX15 P16050 1/20 0.41
HIF1A Q16665 1/20 0.40
ULK1 O75385 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541117 0.93 TSHR (0.47) KMT2AMEN1MAPTKDM4EALDH1A1
SCHEMBL5546508 0.89 MEN1 (0.50) KMT2AMEN1KDM4ESMN1; SMN2L3MBTL1
SCHEMBL5543186 0.89 CYP2C19 (0.47) KMT2AMEN1KDM4EALDH1A1HSD17B10
SCHEMBL5546772 0.88 CNR2 (0.49) KMT2AMEN1TSHRCNR2HTR3A
SCHEMBL4715876 0.88 MEN1 (0.49) KMT2AMEN1KDM4EL3MBTL1TSHR
SCHEMBL5538979 0.87 MEN1 (0.48) KMT2AMEN1KDM4EALDH1A1HSD17B10
SCHEMBL4713762 0.87 MEN1 (0.48) KMT2AMEN1KDM4EL3MBTL1TSHR
Gsk-364735 SCHEMBL5545304 0.87 KDM4E (0.53) KMT2AMEN1KDM4EL3MBTL1TSHR
SCHEMBL5545906 0.86 MEN1 (0.48) KMT2AMEN1KDM4EL3MBTL1TSHR
SCHEMBL5539034 0.86 MEN1 (0.51) KMT2AMEN1KDM4EL3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 KMT2A 502/4885MEN1 4802/4885KCNH2 3380/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 KMT2A 819/4885MEN1 4837/4885KCNH2 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.